Furegrelate Sodium 是口服有效的、血栓素合酶选择性抑制剂，抑制人血小板微粒体血栓素 A2 (TxA2) 合酶的 IC50为 15 nM。它正在开发作为抗血小板药物。

Furegelate sodium is a selective thromboxane synthase inhibitor with oral activity. Furegrelate sodium inhibits thromboxane A2 (TXA2) synthase in human platelet microsomes with an IC50 of 15 nM.

Furegrelate also is orally available, has a long half-life of 4.2–5.8 hours in adult humans (compared to several other therapies for PAH including nitric oxide and prostacyclin analogs), and reportedly is highly specific for its target enzyme.Furegrelate Sodium ?(1-5 mg/kg; Oral) prevents blockage of the coronary artery. Furegrelate Sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation. Furegrelate Sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature.

85666-17-7

C15H11NNaO3

276.24

U-63557A

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years